Randomised controlled trials (RCTs) of angiotensin receptor blockers that had median or mean follow-up of at least 12 months and included at least 100 patients were eligible for inclusion. Trials had to report data of cancer occurrence on death. Trials where all groups received an angiotensin receptor blocker were excluded.
Angiotensin receptor blockers assessed in the included trials were losartan, telmisartan alone or combined with ramipril, candesartan, and valsartan alone or combined with captopril. Five trials compared angiotensin receptor blockers with placebo; other comparator agents were atenolol, ramipril, and captopril. Patients in the included trials had pre-hypertension/hypertension, cardiovascular disease, diabetes, recent ischaemic stroke, heart failure, and year acute myocardial infarction. The mean age of participants ranged from 48 to 67 years; the proportion of men ranged from 46 to 74%.
The authors did not state how many reviewers selected studies for inclusion.